Abstract 590P
Background
Colorectal cancer (CRC) CRC with peritoneal metastasis (PM) obtain poor prognosis. Peritoneal Cancer Index (PCI) is used to evaluate the PM extent and selection of Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). However, PCI score assessed before surgery is not precise.We have developed a novel AI framework of DeAF (Decoupling feature alignment and fusion) to aid the selection and predict completeness of CRS in PM.
Methods
185 CRC patients with PM recruited from four tertiary hospitals were enrolled. The internal patient cohort was subsequently stratified into training and validation cohorts, comprising 84 and 30 individuals, respectively. Deep learning was used to train the DeAF model of Simsam algorithms by contrast CT images and then cooperate with clinicopathological parameters to increase the performance. The performance was evaluated by accuracy, sensitivity, specificity, and AUC by ROC in the internal and external validation cohorts.
Results
The AI model demonstrated a robust ability to predict the completeness of CRS with AUC of 0.9 in internal validation cohort. The model can predict whether patients are suitable for CRS. It can differentiate patients who would benefit from CRS. The model also showed high predictive performance of CRS completeness in external validation cohorts with AUC values of 0.906, 0.960, and 0.933, respectively (rounded to three decimal places).
Conclusions
The novel DeAF framework can aid surgeons to select proper patients for CRS and predict the completeness of CRS. The model can change surgical decision-making and provide potential benefits for patients with PM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
597P - Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Presenter: Filipa Simões
Session: Poster session 16
598TiP - PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Presenter: Thomas Aparicio
Session: Poster session 16
599TiP - PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Presenter: Tomoki Sakakida
Session: Poster session 16
600TiP - A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Presenter: Maria Elena Elez Fernandez
Session: Poster session 16
601TiP - A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Presenter: Ilya Pokataev
Session: Poster session 16
602TiP - Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Presenter: Jun Huang
Session: Poster session 16
454P - Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Presenter: Juan Manuel Sepúlveda
Session: Poster session 16
455P - Phase II trial of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer
Presenter: Yatian Liu
Session: Poster session 16
456P - Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Presenter: Manuel Alejandro Mazariegos-Rubi
Session: Poster session 16
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16